SUMMARY Bethanechol, a muscarinic cholinergic agonist, was injected subcutaneously in eight cases of senile dementia of the Alzheimer type. Simple reaction time was measured before, 15 min and 30 min following the injection. Before injection, the patients had significantly longer reaction time than non-demented controls. A significant shortening of the reaction time was observed 15 min but not 30 min after injection. A second group of eight patients with senile dementia of the Alzheimer type, matched for age and mental impairment were injected with saline. No significant shortening of the reaction time was observed. These results suggest that the reaction time can be shortened by a muscarinic agonist in dementia of the Alzheimer type. [60][61][62][63][64][65][66][67][68][69][70][71][72][73][74][75][76][77][78][79]. They were also matched for the level of deterioration as assessed by the mental status questionnaire (MSQ) score7: mean ± SEM in group I: 6-5 + 0 9, range 3-10 and in group II: 7-3 ± 0-8, range 5-10.
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The task was a simple reaction time paradigm. The subjects were asked to depress a switch with their index finger, as fast as possible, when a red light located near the switch was turned on. The light was turned on at random intervals of time. The switch was connected to an electronic clock (Rochar A926). After ten practice trials, the reaction time was measured for 20 additional trials. The mean reaction time was calculated from these 20 trials. Three consecutive series of trials were administered: the first prior to any injection, the second 15 minutes and the third 30 minutes following the injection of bethanechol or saline. The occurrence of side effects was carefully checked. In group I, the most common side effects were micturition and in two cases only, abdominal cramps. Heart rate and blood pressure (monitored every 5 minutes) were not significantly modified by bathenechol injections. In group II no side effect was observed.
Results
In a preliminary study, the simple reaction time (RT) was measured in 54 normal subjects, in two classes of age: in the first group (range of age 20-49, n = 30), the mean + SEM reaction time value was 247 + 7 ms. In the second group (range of age 50-94, n = 24), the mean ± SEM value was 314 + 17 ms. We also measured simple reaction time in non demented Parkinsonian patients (n = 10, mean age 68 ± 2-3, MSQ = 9 7 + 0.2). The The only side effect observed in group I patients was micturition (all patients), usually occurring between the second and the third series of trials.
Abdominal cramps were observed in two patients. These side effects did not disturb the experimental sessions.
Discussion
Our results provide evidence that the reaction time of Alzheimer type dementia patients is shortened by prior injection of the muscarinic agonist (Table 1) or saline  (Table 2) injection. D% indicates the differences (in percent) between T6-T,, T,,-T30 and T6-T30 respectively (from the left to the right).
Mean differences are given at the bottom of each bethanechol. This shortening is not due to learning since it was not observed in Alzheimer type dementia patients performing the same task but receiving only saline (table 2) .
One might suggest that the shortening of the reaction time is due to an indirect effect, namely the effect of bethanechol on peripheral and not central muscarinic receptors, being responsible for an arousal reaction via indirect stimulation of visceral receptors. However, this explanation seems unlikely, since the peripheral effects of the drug were usually limited to micturition and most of the patients were indifferent to it and did not report any painful sensation. Therefore, it is likely that the shortening of the reaction time is due to the central effect of the drug. Preliminary results of long term oral'0 and of ventricular'0 administration of bethanechol seem to support this hypothesis.
The marked variation in reaction time values observed between and within Alzheimer type dementia patients seems to be a feature of dementia since it was not observed in normal subjects or Parkinsonian patients. Furthermore, the lengthening of the reaction time in Alzheimer type dementia patients was positively correlated with the severity of the deterioration (P Davous, unpublished observation). However, given such a variability, it would be necessary to confirm the present results by a cross-over randomly assigned trial.
In conclusion, our results confirm that some deficits in Alzheimei s disease are sensitive to cholinergic drugs and that further clinical trials with muscarinic agonists are worthwhile. They also emphasise the usefulness of the reaction time paradigm as a tool for the psychopharmacological investigation of Alzheimer type dementia patients.
